{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:56:07Z","timestamp":1790643367877,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":117,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Eat Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, induces potent appetite suppression and substantial weight loss. Increasing access to incretin-based therapies through online services has raised concerns regarding metabolic and psychiatric complications, particularly in vulnerable individuals. We report a case of starvation ketosis associated with self-administered tirzepatide, followed by the clinical recognition of anorexia nervosa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 21-year-old woman with no prior formal psychiatric or metabolic diagnoses had a 2-month history of dieting behaviors and intermittent binge-purge symptoms before tirzepatide initiation. Seeking further weight loss, she obtained tirzepatide through an online medical service and self-administered 2.5\u00a0mg weekly for approximately 4 weeks, followed by 5.0\u00a0mg weekly for another month, without direct medical supervision. She reportedly stated during the online consultation that she was overweight. Her body weight decreased from 47\u00a0kg to 41\u00a0kg (BMI 17.9 to 15.6\u00a0kg\/m\u00b2). Approximately 2 months after initiation, she developed severe nausea, bilious vomiting, and presyncope, requiring emergency admission. Tirzepatide had been discontinued shortly before admission because of nausea. Laboratory evaluation revealed marked ketonemia (serum 3-hydroxybutyrate 2057 \u00b5mol\/L), normoglycaemia (glucose 79\u00a0mg\/dL), mildly elevated anion gap, normal HbA1c (5.1%), and no clinically significant acidaemia. She had no history of SGLT2 inhibitor use or habitual alcohol consumption. She was diagnosed with starvation ketosis and improved with intravenous glucose infusion and nutritional support. Shortly after discharge, psychiatric evaluation by a board-certified psychiatrist led to a diagnosis of anorexia nervosa, binge-eating\/purging type. At early follow-up, body weight had increased to 42\u00a0kg, the Eating Attitudes Test-26 (EAT-26) score decreased to 14, but serum 3-hydroxybutyrate remained elevated at 166 \u00b5mol\/L. At later outpatient reassessment several months later, body weight remained 42\u00a0kg, serum 3-hydroxybutyrate had normalized to 24 \u00b5mol\/L, and the EAT-26 score was 16; however, her drive for thinness persisted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case highlights that unsupervised tirzepatide use may be associated with starvation ketosis and the clinical recognition or exacerbation of eating-disorder psychopathology. Metabolic recovery did not parallel full improvement in eating-disorder symptoms, underscoring the need for careful screening, longitudinal psychiatric follow-up, and interdisciplinary management when incretin-based therapies are used.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40337-026-01666-y","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:26:15Z","timestamp":1780575975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Starvation ketosis following self-administered tirzepatide obtained via online services in a young woman later diagnosed with anorexia nervosa: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Norio","family":"Yasui-Furukori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasumi","family":"Tasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kamiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimasa","family":"Aso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"issue":"1","key":"1666_CR1","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","volume":"393","author":"LJ Aronne","year":"2025","unstructured":"Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025;393(1):26\u201336.","journal-title":"N Engl J Med"},{"issue":"11","key":"1666_CR2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"2","key":"1666_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/eat.24109","volume":"57","author":"S Bartel","year":"2024","unstructured":"Bartel S, McElroy SL, Levangie D, Keshen A. Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. Int J Eat Disord. 2024;57(2):286\u201393.","journal-title":"Int J Eat Disord"},{"key":"1666_CR4","first-page":"100333","volume":"35","author":"L Aoun","year":"2024","unstructured":"Aoun L, Almardini S, Saliba F, Haddadin F, Mourad O, Jdaidani J, et al. GLP-1 receptor agonists: a novel pharmacotherapy for binge eating (binge eating disorder and bulimia nervosa)? A systematic review. J Clin Transl Endocrinol. 2024;35:100333.","journal-title":"J Clin Transl Endocrinol"},{"issue":"9","key":"1666_CR5","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.3390\/jcm14093122","volume":"14","author":"M Ka\u0142as","year":"2025","unstructured":"Ka\u0142as M, St\u0119pniewska E, Gniedziejko M, Leszczy\u0144ski-Czeczatka J, Siemi\u0144ski M. Glucagon-like peptide-1 receptor agonists in the context of eating disorders: a promising therapeutic option or a double-edged sword? J Clin Med. 2025;14(9):3122.","journal-title":"J Clin Med"},{"issue":"3","key":"1666_CR6","doi-asserted-by":"publisher","first-page":"298","DOI":"10.7861\/clinmed.2020-0012","volume":"20","author":"AJ Gall","year":"2020","unstructured":"Gall AJ, Duncan R, Badshah A. Starvation ketoacidosis on the acute medical take. Clin Med (Lond). 2020;20(3):298\u2013300.","journal-title":"Clin Med (Lond)"},{"issue":"8","key":"1666_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s00125-024-06183-8","volume":"67","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez GE, Davis GM, ElSayed NA, Fadini GP, Galindo RJ, Hirsch IB, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024;67(8):1455\u201379.","journal-title":"Diabetologia"},{"issue":"9","key":"1666_CR8","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1038\/s41591-025-03774-9","volume":"31","author":"CK Martin","year":"2025","unstructured":"Martin CK, Carmichael OT, Carnell S, Considine RV, Kareken DA, Dydak U, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial. Nat Med. 2025;31(9):3141\u201350.","journal-title":"Nat Med"},{"issue":"2","key":"1666_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/JCP.0000000000001820","volume":"44","author":"AI Guerdjikova","year":"2024","unstructured":"Guerdjikova AI, Ward A, Ontiveros M, McElroy SL. Semaglutide misuse in atypical anorexia nervosa: a case report. J Clin Psychopharmacol. 2024;44(2):179\u201380.","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"1666_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/JCP.0000000000001975","volume":"45","author":"AI Guerdjikova","year":"2025","unstructured":"Guerdjikova AI, Dlugosz H, Wolterman R, McElroy SL. Relapse in anorexia nervosa associated with tirzepatide: a case report. J Clin Psychopharmacol. 2025;45(3):287\u20138.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1666_CR11","first-page":"25cr03931","volume":"27","author":"MK Mudd","year":"2025","unstructured":"Mudd MK, Rado JT. Mental health effects of tirzepatide: a report of 2 patients. Prim Care Companion CNS Disord. 2025;27(4):25cr03931.","journal-title":"Prim Care Companion CNS Disord"},{"key":"1666_CR12","doi-asserted-by":"publisher","first-page":"1330936","DOI":"10.3389\/fendo.2024.1330936","volume":"15","author":"W Chen","year":"2024","unstructured":"Chen W, Cai P, Zou W, Fu Z. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database. Front Endocrinol (Lausanne). 2024;15:1330936.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1666_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1017\/S0033291700049163","volume":"12","author":"DM Garner","year":"1982","unstructured":"Garner DM, Olmsted MP, Bohr Y, Garfinkel PE. The eating attitudes test: psychometric features and clinical correlates. Psychol Med. 1982;12(4):871\u20138.","journal-title":"Psychol Med"},{"issue":"1","key":"1666_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s40519-024-01669-1","volume":"29","author":"N Nohara","year":"2024","unstructured":"Nohara N, Hiraide M, Horie T, Takakura S, Hata T, Sudo N, et al. The optimal cut-off score of the Eating Attitude Test-26 for screening eating disorders in Japan. Eat Weight Disord. 2024;29(1):42.","journal-title":"Eat Weight Disord"},{"key":"1666_CR15","unstructured":"U.S. Food and Drug Administration. FDA\u2019s concerns with unapproved GLP-1 drugs used for weight loss. Available from: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed 30 Mar 2026."},{"issue":"1","key":"1666_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.psc.2025.08.013","volume":"49","author":"LM Schaefer","year":"2026","unstructured":"Schaefer LM, Kerver GA, Allison KC, Kohoutek B, Steffen KJ. Use (and potential for abuse) of glucagon-like peptide-1 medications among individuals with eating disorders: empirical review and clinical guidance. Psychiatr Clin North Am. 2026;49(1):183\u2013202.","journal-title":"Psychiatr Clin North Am"}],"container-title":["Journal of Eating Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40337-026-01666-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-026-01666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40337-026-01666-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:59:42Z","timestamp":1790639982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40337-026-01666-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1666"],"URL":"https:\/\/doi.org\/10.1186\/s40337-026-01666-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9289959\/v1","asserted-by":"object"}]},"ISSN":["2050-2974"],"issn-type":[{"value":"2050-2974","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not required for this case report in accordance with institutional policy.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and the accompanying table.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"227"}}